3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
3
Melanoma
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Lymphatic Metastasis
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Anus Neoplasms
1
Interventions
Surveys and Questionnaires
6
Methods
6
Radiotherapy
5
Cisplatin
5
pembrolizumab
4
durvalumab
3
Sentinel Lymph Node Biopsy
3
Radiosurgery
3
Palliative Care
3
Indocyanine Green
3
Early Intervention, Educational
3
Brachytherapy
3
Bleomycin
3
tremelimumab
2
aldesleukin
2
Surgical Procedures, Operative
2
Radiation
2
Paclitaxel
2
Interviews as Topic
2
Immunoglobulin G
2
Imiquimod
2
Gemcitabine
2
Electrochemotherapy
2
Drug Therapy
2
Disulfides
2
Dehydroepiandrosterone
2
Counseling
2
Carboplatin
2
Biopsy
2
Bevacizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Vulvar Neoplasms
×
Technetium-99
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled